HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

IDX320

an HCV protease inhibitor

Networked: 1 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - IDX320: 1

Experts

1.	Chen, Jie: 1 article (01/2012)
2.	Cholewińska-Szymańska, Grażyna: 1 article (01/2012)
3.	Kapocsi, Judit: 1 article (01/2012)
4.	Mayers, Douglas: 1 article (01/2012)
5.	Mazur, Włodzimierz: 1 article (01/2012)
6.	McCarville, Joseph F: 1 article (01/2012)
7.	Molles, Jeffrey: 1 article (01/2012)
8.	Pietropaolo, Keith: 1 article (01/2012)
9.	Reesink, Hendrik: 1 article (01/2012)
10.	Simon, Krzysztof: 1 article (01/2012)

Related Diseases

1.	Infections 01/01/2012 - "This was a randomized double-blind placebo-controlled single- and multiple-dose study to assess the safety, tolerability, antiviral activity and pharmacokinetics of IDX320 in healthy volunteers (HV) and patients with chronic HCV genotype 1 infection. "
2.	Chronic Hepatitis C 01/01/2012 - "Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor."

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	Viral RNA
3.	Protease Inhibitors (Protease Inhibitor)